CrizotinibDe novo acquisition of MET D1228N mutation in MET-amplified triple-negative breast cancer: case report

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2018年 / 1718卷 / 1期
关键词：
D O I：
10.1007/s40278-018-51426-z
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：82 / 82
相关论文
共 50 条
  • [1] Cabozantinib/crizotinibDe novo acquisition of MET D1228N mutation in MET-amplified triple-negative breast cancer and progression of disease with various toxicities
    Reactions Weekly, 2022, 1887 (1) : 164 - 164
  • [2] Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer
    Parsons, Benjamin M.
    Meier, David R.
    Richmond, Craig S.
    Gurda, Grzegorz T.
    Lofgren, Kristopher A.
    Burkard, Mark E.
    Deming, Dustin A.
    Kenny, Paraic A.
    CLINICAL BREAST CANCER, 2020, 20 (04) : E433 - E438
  • [3] Emergence of MET D1228N mutation as a resistance mechanism following an exceptional response to crizotinib in a MET-amplified triple-negative breast cancer patient
    Parsons, Benjamin M.
    Meier, David R.
    Gurda, Grzegorz T.
    Lofgren, Kristopher A.
    Kenny, Paraic A.
    CANCER RESEARCH, 2018, 78 (13)
  • [4] Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer
    Zhang, Shubing
    Chung, Wen-cheng
    Miele, Lucio
    Xu, Keli
    CANCER BIOLOGY & THERAPY, 2014, 15 (05) : 633 - 642
  • [5] Exceptional Response to Crizotinib in an MET-Amplified Triple-Negative Breast Tumor
    Parsons, Benjamin M.
    Meier, David R.
    Gurda, Grzegorz T.
    Lofgren, Kristopher A.
    Kenny, Paraic A.
    JCO PRECISION ONCOLOGY, 2017, 1
  • [6] MET D1228N and D1246N are the Same Resistance Mutation in MET Exon 14 Skipping
    Tsai, Jonathan M.
    Hata, Aaron N.
    Lennerz, Jochen K.
    ONCOLOGIST, 2021, 26 (12): : E2297 - E2301
  • [7] Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation
    Pruis, Melinda A.
    Paats, M. S.
    Geurts, W. R. R.
    Dubbink, H. J.
    Dingemans, A-M C.
    JCO PRECISION ONCOLOGY, 2021, 5 : 849 - 853
  • [8] A rapid and durable response to cabozantinib in an osimertinib- resistant lung cancer patient with MET D1228N mutation: a case report
    Kuang, Yukun
    Wang, Jiyu
    Xu, Peihang
    Zheng, Yifan
    Bai, Lihong
    Sun, Xue
    Li, Zimu
    Gan, Runjing
    Li, Huixia
    Ke, Zunfu
    Tang, Kejing
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (16)
  • [9] Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation
    Zhu, Jinlian
    Chen, Jie
    Liu, Wei
    Zhang, Junling
    Gu, Yulan
    LUNG CANCER-TARGETS AND THERAPY, 2024, 15 : 123 - 128
  • [10] CapmatinibAcquired MET D1228H mutation: case report
    Reactions Weekly, 2024, 2026 (1) : 73 - 73
12345